Sanofi and Regeneron likely to cough up royalties to end Amgen’s PCSK9 patent suit: Analyst

Tracy Staton One of the hottest races for market share in pharma these days is between Amgen's cholesterol-fighter Repatha and Praluent, from Sanofi and Regeneron. They're apparently ...

Sanofi and Regeneron line up for second place in EU cardio race

Damian Garde Sanofi and Regeneron may be on pace to win the first U.S. approval for a new type of cholesterol treatment, but the pair trails rival Amgen in Europe in a race to make ...

UPDATED: Sanofi and Regeneron pick up a blockbuster cardio approval–with a catch

Damian Garde Sanofi and Regeneron won an expected FDA approval for the first of a new class of cholesterol drugs expected to alter the landscape in cardiology, but regulators stopped ...

Eylea expected to keep delivering for Regeneron as Praluent starts to step up

Carly Helfand Eye blockbuster Eylea has been churning out serious revenue growth for Regeneron since it hit the market, and now the company is inching closer to approval for its much-watched ...

Regeneron speeds toward the FDA with its would-be asthma blockbuster

Damian Garde Regeneron has advanced dupilumab, regarded by many as the company's next big innovation, into a Phase III asthma study, rolling toward an FDA submission behind its ...

Eyeing Eylea’s heirs, Regeneron spends more and more on R&D

Damian Garde Regeneron is pouring more money than ever into its well-respected R&D operation, spending big on a cadre of late-stage candidates the Big Biotech believes can outshine ...

Here’s a first: Regeneron cuts forecast after hard-charging Eylea sales miss

Carly Helfand Here's something Regeneron isn't used to: Cutting sales forecasts for blockbuster eye drug Eylea. But that's just what the New York biotech did Tuesday amid ...

Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

John Carroll FierceBiotech News

Sanofi, Regeneron pay $67.5M for a regulatory shortcut in blockbuster PCSK9 race with Amgen

John Carroll Sanofi and Regeneron just stole a march on Amgen in the race to get their PCSK9 cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening ...

Regeneron, Sanofi herald a blockbuster contender with groundbreaking study

John Carroll If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data ...

Regeneron R&D chief’s compensation shrinks, but still tops the chart

John Carroll FierceBiotech News

Busy Regeneron busts Eylea sales forecasts, re-ups with Sanofi

Tracy Staton Yesterday, Regeneron CEO Len Schleifer announced that rather than the $ 377 million expected by analysts, Regeneron will report about $ 400 million in U.S. sales for macular ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS